Massa. Autoimmune drug discovery, structurally.
An AI-driven engine for detecting molecular mimicry between pathogens and human proteins — one of the strongest current hypotheses for what triggers autoimmune disease. From target identification to clinical validation, on a single pipeline.
Autoimmune drug discovery is mostly empirical and slow.
Most autoimmune therapies still emerge from broad immunosuppression, repurposing, or trial-and-error. Molecular mimicry — the mechanism by which pathogen proteins resemble human proteins enough to trigger an autoimmune response — is one of the most structurally compelling explanations for autoimmune onset. Massa turns that hypothesis into infrastructure pharma teams can actually use.
A pipeline from hypothesis to candidate.
Target identification
AI models trained to detect structural and sequence similarity between pathogen proteins and human self-antigens across autoimmune conditions.
Cross-disease pattern detection
Shared mimicry signatures across multiple autoimmune conditions — useful for understanding comorbidity and identifying broader therapeutic targets.
Validation pipeline
Integration with experimental validation workflows. From in silico prediction to wet-lab confirmation, designed as a continuous loop, not a handoff.
Clinical correlation
When connected with MAR Platform datasets, candidate targets can be cross-referenced against real clinical and PROM data — closing the loop between molecular hypothesis and patient outcome.
Pharma-grade IP framework
Built for collaboration with pharma R&D. Clear IP boundaries, audit trails, regulatory-grade documentation from day one.
Therapeutic candidates
Outputs designed to feed directly into pharma's existing drug development pipelines — from monoclonal antibodies to small molecules to peptide-based therapies.
Not in development. In optimisation.
Cypher is the sequence-similarity detection engine that powers Massa. In 24 months it has gone from proof of concept to a throughput that makes previously intractable searches routine.
Pharma is the client.
Unlike Maia Clinical and Maia, Massa serves pharma as a direct client — under a different commercial model and with a different data class. There is full separation between Massa's pharma operations and the patient-facing products. No patient data from Maia is ever transferred to Massa without explicit, study-specific consent.
Why structural mimicry, why now.
The biological frame
Mimicry is increasingly understood as a unifying mechanism across autoimmune diseases. Targeting it directly — rather than treating downstream inflammation — opens entirely new therapeutic strategies.
AI at the right scale
Detecting structural mimicry across the protein universe is a computational problem that has only recently become tractable. Cypher is the proof that we are at that inflection point.
The European data layer
MAR Platform and Maia provide real-world clinical and PROM data that no US-based discovery platform can replicate. That changes what kind of candidate validation is possible.
Integrated, not bolted on
Most computational drug discovery tools sit apart from clinical data. Massa is part of an architecture where discovery and clinical evidence speak the same language.
Pharma conversations begin at BioSpain.
Other Neural Omega products
The conversation starts in Bilbao.
If your team is exploring molecular mimicry as a therapeutic angle in autoimmune disease, BioSpain 2026 is where we want to talk. Pre-arranged meetings are available now.
Explore pharma partnerships →